Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $126.4052W HIGH $354.88
Volume
1.53 M
Value Traded
214.58 M
Short % Float
7.76%
Days to Cover
3.9
+4.64%Week
+12.13%1 Month
-10.87%3 Month
-18.38%6 Month
-39.07%5 Year
+811%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.35 B
EPS (TTM)
5.41
P/E Ratio
27.58
Ent. Value
9.84 B
Total Shares
69.35 M
Float Shares
69.05 M
Insiders
0.44%
Institutions
106.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PODD Catalyst Timeline
Dated clinical, regulatory and corporate events for Insulet Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Insulet Corporation
8Total events
0Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How PODD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Insulet Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PODD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McEvoy AshleyDirector, Officer (President and CEO) | Buy | 1,100 23,731 held | $147.47 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PODD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 5.5 % (14.6 %) | 159.71 M | 1.05 M | 86.49% ( 486.50 K) |
PODD Institutional Ownership Trends
PODD Short Interest
Shares sold short, counted twice a month.
7.76%
Short % of Float
of tradable shares sold short
5.4M
Shares Sold Short
+5.4% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PODD ranks across every disease it competes in
Competitive Position is a premium feature
See how PODD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPODD News
PODDInsulet Announces Omnipod Discover Now Available in U.S.
Insulet Corporation has announced the full market release of Omnipod Discover in the U.S. This innovative web-based data platform is designed for users of the Omnipod 5 insulin pump, providing critical diabetes data visualizations and personalized insights. The platform aims to enhance collaboration between users and healthcare providers.
Read more →PODDInsulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Insulet Corporation has announced that it will report its financial results for the third quarter of 2026 on November 4, 2026. The report will be released before the markets open, followed by a conference call at 8:00 a.m. Eastern Time. This event highlights the company's commitment to keeping stakeholders informed.
Read more →PODDInsulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Insulet Corporation announced its participation in the Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum scheduled for September 24, 2026. The event will feature a presentation by management at 12:30 p.m. ET, with a live webcast available for investors. This participation underscores Insulet's leadership in the insulin pump market.
Read more →PODDInsulet to Participate in Wells Fargo 21st Annual Healthcare Conference
Insulet Corporation will present at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will take place in Boston at 2:15 p.m. Eastern Time. A live webcast and replay will be available on the company's Investor Relations website, providing access to key insights.
Read more →PODD▼ -20.1%on this news
Insulet Reports Second Quarter 2026 Results
Insulet Corporation reported its financial results for Q2 2026, showcasing a revenue of $801.7 million, which represents a 23.5% increase compared to the previous year. This growth surpassed the company's guidance range of 20% to 22% in constant currency. The Omnipod product line contributed significantly, with total revenue of $795.9 million.
Read more →PODDInsulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss
Insulet Corporation has partnered with Calm to provide emotional well-being resources for individuals living with diabetes. This collaboration marks Calm's first integrated content partnership with a MedTech company, aiming to support patients, caregivers, and healthcare professionals. The initiative includes mindfulness tools and a new sleep story narrated by Lila Moss.
Read more →PODDInsulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology
Insulet Corporation has announced the launch of its Omnipod® 5 and Omnipod Discover™ in Spain, marking a significant step in expanding access to its tubeless diabetes management technology. This launch is part of Insulet's strategy to accelerate its global growth and enhance the lives of individuals with diabetes. The introduction of these products aims to provide more patients with innovative solutions for diabetes care.
Read more →PODDInsulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
Insulet Corporation is set to announce its financial results for the second quarter of 2026 on August 5, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are expected to review the results for insights into the company's performance.
Read more →PODDInsulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Insulet has announced the appointment of Jonathan J. Mazelsky to its Board of Directors. This move is part of the company's strategy to enhance its leadership team. Further details about Mazelsky's background or the implications of this appointment were not provided in the announcement.
Read more →PODD▼ -5.1%on this news
Insulet to Participate in William Blair 46th Annual Growth Stock Conference
Insulet Corporation is set to participate in the William Blair 46th Annual Growth Stock Conference. The event will provide an opportunity for the company to engage with investors and discuss its growth strategies. Further details about the conference and Insulet's presentation have not been disclosed.
Read more →PODDInsulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
Insulet has announced a voluntary medical device correction affecting certain Omnipod® Pods. This correction applies to both the U.S. and international markets, indicating potential safety concerns. The company is addressing issues that may affect the performance and reliability of the devices, which could impact users significantly.
Read more →PODD▼ -9.7%on this news
Insulet Reports First Quarter 2026 Results Raises Full Year Total Company Revenue Guidance
Insulet Corporation reported a strong financial performance for the first quarter of 2026, with revenues reaching $761.7 million, up 33.9% from the previous year. The company increased its full-year revenue guidance, citing significant growth in both U.S. and international markets. Noteworthy milestones included the launch of Omnipod 5 in multiple countries and advancements in their automated insulin delivery technology. Overall, Insulet demonstrated robust growth prospects and innovative product enhancements.
Read more →PODD▼ -9.7%on this news
Insulet Reports First Quarter 2026 Results
Insulet Corporation reported strong financial results for Q1 2026, with revenues of $761.7 million, a 33.9% increase compared to the previous year. The company achieved notable growth in both U.S. and international markets, particularly with its Omnipod product line. Insulet also announced the launch of new products and advancements in automated insulin delivery technology, raising its revenue growth outlook for the year.
Read more →PODDInsulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
Insulet has released its 2025 Sustainability Report, which emphasizes the company's progress in key areas. The report outlines various initiatives aimed at enhancing sustainability and corporate responsibility. However, specific details regarding the report's findings and metrics are not provided in the article.
Read more →PODDInsulet to Participate in BofA Securities 2026 Health Care Conference
Insulet Corporation announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 13, 2026. The presentation will showcase Insulet's advancements in insulin delivery technology, particularly the Omnipod product line. The event will be accessible via a live webcast on the company's Investor Relations website.
Read more →PODDInsulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation announced it will report its financial results for the first quarter of 2026 on May 6, 2026. The announcement includes details about a conference call scheduled for the same day at 8:00 a.m. Eastern Time. The call will be accessible via the company's Investor Relations website and by phone for both domestic and international callers.
Read more →PODDInsulet Initiates Voluntary Medical Device Correction for Certain Omnipod 5 Pods in the U.S.
Insulet Corporation has announced a voluntary Medical Device Correction for specific lots of its Omnipod 5 Pods in the U.S. due to a manufacturing issue that may lead to insulin leakage. Although this affects 1.5% of annual production, the company has assured that all other Omnipod products remain safe for use. Insulet has notified the FDA and is providing affected customers with replacement Pods at no cost. The company continues to maintain normal operations and does not anticipate any disruptions in product availability.
Read more →PODDInsulet Reports Fourth Quarter and Full Year 2025 Results
Insulet Corporation reported a 31% increase in revenue for both the fourth quarter and full year of 2025, marking its tenth consecutive year of significant growth. The company received board approval for a $350 million increase in share repurchase authorization, demonstrating its strong financial position. Insulet's CEO expressed confidence in the company's ability to expand its market presence and deliver long-term value.
Read more →PODDInsulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover in the Middle East, including Saudi Arabia, Kuwait, Qatar, and the UAE. This launch aims to address the significant unmet needs of diabetes care in the region. The Omnipod 5 system automates insulin delivery and has demonstrated improved glycemic outcomes. Omnipod Discover offers a user-friendly data management platform for better diabetes management.
Read more →PODDInsulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
Insulet Corporation will announce its financial results for Q4 and the full year of 2025 on February 18, 2026. The announcement will be made before the market opens, followed by a conference call at 8:00 a.m. ET. The call will be accessible via the company's Investor Relations website and by phone.
Read more →About Insulet Corporation
Headquarters100 NAGOG PARK, ACTON, MA, 01720
BIOPHARMAWATCH ELITE PLUS
Trade the next PODD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime